ITPA Antibody

Code CSB-PA910876
Size US$166
Order now
Image
  • The image on the left is immunohistochemistry of paraffin-embedded Human brain tissue using CSB-PA910876(ITPA Antibody) at dilution 1/30, on the right is treated with fusion protein. (Original magnification: ×200)
  • The image on the left is immunohistochemistry of paraffin-embedded Human liver cancer tissue using CSB-PA910876(ITPA Antibody) at dilution 1/30, on the right is treated with fusion protein. (Original magnification: ×200)
  • Gel: 12%SDS-PAGE,Lysate: 40 μg,Lane 1-2: Human fetal liver tissue, Hela cells,Primary antibody: CSB-PA910876(ITPA Antibody) at dilution 1/200 dilution,Secondary antibody: Goat anti rabbit IgG at 1/8000 dilution,Exposure time: 2 minutes
Have Questions? Leave a Message or Start an on-line Chat

Product Details

Uniprot No.
Target Names
ITPA
Alternative Names
C20orf37 antibody; dJ794I6.3 antibody; HLC14-06-P antibody; Inosine triphosphatase (nucleoside triphosphate pyrophosphatase) antibody; Inosine triphosphatase antibody; inosine triphosphatase-A antibody; Inosine triphosphate pyrophosphatase antibody; Inosine triphosphate pyrophosphohydrolase antibody; Itpa antibody; ITPA_HUMAN antibody; ITPase antibody; My049 antibody; My049 protein antibody; Non canonical purine NTP pyrophosphatase antibody; Non standard purine NTP pyrophosphatase antibody; NTPase antibody; nucleoside triphosphate diphosphatase antibody; Nucleoside triphosphate pyrophosphatase antibody; OK/SW-cl.9 antibody; OTTHUMP00000030094 antibody; OTTHUMP00000160459 antibody; Putative oncogene protein hlc14-06-p antibody
Raised in
Rabbit
Species Reactivity
Human,Mouse,Rat
Immunogen
Full length fusion protein
Immunogen Species
Homo sapiens (Human)
Conjugate
Non-conjugated
Isotype
IgG
Purification Method
Antigen affinity purification
Concentration
It differs from different batches. Please contact us to confirm it.
Buffer
-20°C, pH7.4 PBS, 0.05% NaN3, 40% Glycerol
Form
Liquid
Tested Applications
ELISA,WB,IHC
Recommended Dilution
Application Recommended Dilution
ELISA 1:1000-1:2000
WB 1:200-1:1000
IHC 1:10-1:50
Troubleshooting and FAQs
Storage
Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
Lead Time
Basically, we can dispatch the products out in 1-3 working days after receiving your orders. Delivery time maybe differs from different purchasing way or location, please kindly consult your local distributors for specific delivery time.

Customer Reviews and Q&A

 Customer Reviews

There are currently no reviews for this product.

Submit a Review here

Target Background

Function
Pyrophosphatase that hydrolyzes the non-canonical purine nucleotides inosine triphosphate (ITP), deoxyinosine triphosphate (dITP) as well as 2'-deoxy-N-6-hydroxylaminopurine triposphate (dHAPTP) and xanthosine 5'-triphosphate (XTP) to their respective monophosphate derivatives. The enzyme does not distinguish between the deoxy- and ribose forms. Probably excludes non-canonical purines from RNA and DNA precursor pools, thus preventing their incorporation into RNA and DNA and avoiding chromosomal lesions.
Gene References into Functions
  1. Inosine triphosphate pyrophosphatase dephosphorylates ribavirin triphosphate, and reduced enzymatic activity potentiates mutagenesis in hepatitis C virus. PMID: 30045981
  2. This study suggests that the polymorphisms in the ITPA gene influence the severity of anaemia during the first month of a DAA/RBV-based treatment in HCV-related cirrhosis. PMID: 28165327
  3. baseline testing of this single ITPA SNP might help to identify the subset of patients with the greatest risk for experiencing RBV-induced anaemia, which may be particularly helpful in those with underlying cardiovascular disease. In such patients, RBV-sparing regimens should be preferred. PMID: 28198349
  4. The authors analysed ITPA-deficient human and mouse cells, and revealed that ITPA deficiency induces MLH1/PMS2- and p53-dependent growth arrest and DNA instability in mammalian cells. PMID: 27618981
  5. ITPA variant rs1127354C>A significantly predict RBV-induced anaemia during the first 3 months of treatment and it is recommended to be assessed before RBV administration PMID: 28543275
  6. The ITPA gene polymorphism rs1127354 heterozygous genotype (CA) may influence Hemoglobin levels and protect against hemolytic anemia during ribavirin containing regimens for hepatitis C PMID: 28480960
  7. Four gene signature (PTEN, PIK3C2A, ITPA and BCL3) is an independent prognostic factors of both overall survival and disease-free survival in clear-cell renal-cell carcinoma. PMID: 27779101
  8. Inosine triphosphatase polymorphism appeared to correlate with anemia in- cidence and RBV dose reduction during SOF/RBV therapy. PMID: 28109022
  9. Inosine triphosphatase (IPTA) rs1127354 variants but not rs7270101 were found in Chinese patients infected with chronic hepatitis C. IPTA rs1127354 variants and related ITPase were not only related with ribavirin-induced hemolytic anemia but also directly affected the virological response to pegylated interferon plus ribavirin combination therapy in Chinese chronic hepatitis C virus-infected patients. PMID: 28723780
  10. This study concluded that HIV-infection seems to be interfering with the nucleotide metabolism in leukocytes, including CD4 lymphocytes, by decreasing ITPase expression, independently of ITPA genotype. PMID: 27792682
  11. A high prevalence of the ITPA polymorphisms associated with ribavirin-induced hemolytic anemia was found in Mexican Native Amerindians. PMID: 28233743
  12. ITPA gene is associated with protection of anemia in patients with chronic hepatitis during antiviral therapy. PMID: 26110293
  13. We concluded that ITPase activity plays an important function and that ATP concentration changes due to therapy are related to the Hb decreasing mechanism in the early period of therapy with HCV treatment PMID: 27040635
  14. The aim of the study was to investigate frequencies of TPMT and ITPA polymorphisms in Lithuanian inflammatory bowel disease patients and analyze their association with azathioprine-related adverse events. PMID: 26674571
  15. ITPA polymorphism was associated with RBV-induced anemia and thrombocytopenia in Egyptian patients with hepatitis C virus genotype 4 infection. PMID: 26880169
  16. Hyperbilirubinemia develops at early time points after simeprevir administration in most cases and is dependent on the ITPA genotype. PMID: 26223482
  17. Genetic variants in inosine triphosphatase (ITPA) gene have been linked to the haemolytic anaemia induced by peg-interferon and ribavirin treatment. PMID: 26104535
  18. polymorphisms increase the likelihood of developing hemolytic anemia for HCV-infected patients on RBV-based therapy, particularly rs1127354 CC and rs7270101 AA genotypes [meta-analysis] PMID: 26438033
  19. The association of IL28B and APOH single nucleotide polymorphisms (SNPs) with sustained virological response and of ITPA SNPs with anemia related phenotypes. PMID: 26670100
  20. The identification of ITPA protective and SLC29A1 risk genotypes still appears to be a current methodology in Ribavirin dosing during hepatitis C virus therapy with direct acting antiviral agents PMID: 26279293
  21. ITPA SNPs in Brazilian patients receiving antiviral therapy for chronic hepatitis had a great propensity for developing ribavirin-induced anaemia. PMID: 26154744
  22. genotyping of ATIC rs2372536 and ITPA rs1127354 variants or measuring ITPA activity could be useful to predict methotrexate response in children with juvenile idiopathic arthritis. PMID: 25240429
  23. Recessive ITPA mutations were associated with early infantile encephalopathy. PMID: 26224535
  24. results showed that patients with aberrant ITPase genotype (mutant homozygous or heterozygous), more likely to be myelosuppressed and show liver toxicity after treatment with 6-Mercaptopurine PMID: 26242828
  25. The ITPA SNP rs1127354 is a useful predictor of ribavirin-induced anemia in Taiwanese patients and may be related to more severe decreases in platelet counts during the early stage of HCV combination therapy. PMID: 25287171
  26. Results indicate a strong, significant, and independent role of VDR in the early development of ribavirin-induced anemia and confirm the ITPA function in the prediction of anemia at week 4. PMID: 25713999
  27. ITPA polymorphisms are associated with an improved likelihood of achieving sustained virological response resulting from the reduced risk of relapse following IFN and ribavirin combination therapy for HCV infection PMID: 25340831
  28. ITPA genotype may serve as a genetic marker for the improvement of risk stratification and therapy individualization for patients with acute lymphoblastic leukemia. PMID: 25303517
  29. The significant association was found between the rs1127354 ITPA gene polymorphism and protection against ribavirin-induced hemolytic anemia in the Ukrainian patients with chronic hepatitis C infection. PMID: 26030972
  30. Results show that in patients with F3-F4 chronic hepatitis C receiving telaprevir based therapy, ITPA genotype does not impact on the management of early anemia. PMID: 24760000
  31. Partial splenic embolism, in conjunction with triple combination therapy, is a useful and safe method to treat genotype 1b chronic hepatitis C patients with hypersplenism-induced thrombocytopenia PMID: 25743001
  32. the risk of mercaptopurine intolerance was decreased in acute lymphoblastic leukemia patients with 138 allele and 561 allele polymorphism in the ITPA gene PMID: 25120852
  33. important role in hepatitis C virus infection[review] PMID: 24659876
  34. For ITPA, the frequency of P32T allele was 3%. We did not observe any homozygous variant for TPMT and ITPA alleles. PMID: 24774509
  35. Irrespective of the protective effect of ITPA mutations, premenopausal females less likely develop ribavirin induced anemia. PMID: 23850877
  36. All ITPA polymorphisms considered were shown to be significantly associated with anemia onset in chronic hepatitis C treated patients. PMID: 23933495
  37. ITPA protects against ribavirin-induced anemia, but is not associated with sustained virological response rate. PMID: 24449403
  38. ITPA variants are associated with reduced risk of hepatitis C relapse. PMID: 24519039
  39. Study supports recent studies which point towards an important role for ITPase in cellular surveillance of rogue nucleotides.in hematologic malignancy. PMID: 23547827
  40. Non-CC at rs1127354 without involvement of rs7270101 is strongly associated with protection from ribavirin-induced anemia, however, inosine triphosphatase genotype is not associated with sustained virologic response. PMID: 23960450
  41. role of conserved residues in substrate specificity PMID: 23770441
  42. association between ribavirin (RBV) serum levels and SLC28A2 rs11854484 genotype, as well as the replicated association of ITPA and SLC28A3 genetic polymorphisms with RBV-induced anemia and treatment response PMID: 23195617
  43. We propose that the dimer of P32T variant subunit with wild-type subunit is degraded in cells similarly to the P32T homodimer explaining the level of loss of ITPA activity in heterozygotes. PMID: 23528839
  44. ITPA polymorphisms influenced the degree of anaemia but not thrombocytopenia during therapy of chronic hepatitis C genotype 6 infection. PMID: 23730840
  45. Rs1127354 ITPA polymorphism plays a decisive role in protecting against treatment-induced anemia and the need for ribavirin dose reduction in Egyptian hepatitis C patients. PMID: 23538996
  46. ITPA SNPs influence ribavirin-induced anemia in chronic hepatitis C. PMID: 23139603
  47. IL-28B polymorphisms and ITPA variants influence outcome of treatment for chronic hepatitis C with Peg-Interferon and ribavirin. PMID: 23301546
  48. an association was found between ITPA SNP genotype and treatment-induced anemia during a 4-week course of ribavirin monotherapy in patients with chronic hepatitis C PMID: 22460221
  49. patients with the ITPA-CC genotype showed a smaller decrease in platelet counts during natural interferon-beta/ribavirin combination therapy. PMID: 22554247
  50. ITPase C94A has been recognized in about 15% of Japanese bur recent studies on its relationship with thiopurine toxicity has not been clarified. PMID: 23126166

Show More

Hide All

Involvement in disease
Inosine triphosphate pyrophosphohydrolase deficiency (ITPAD); Epileptic encephalopathy, early infantile, 35 (EIEE35)
Subcellular Location
Cytoplasm.
Protein Families
HAM1 NTPase family
Tissue Specificity
Ubiquitous. Highly expressed in heart, liver, sex glands, thyroid and adrenal gland.
Database Links

HGNC: 6176

OMIM: 147520

KEGG: hsa:3704

STRING: 9606.ENSP00000369456

UniGene: Hs.415299

icon of phone
Call us
301-363-4651 (Available 9 a.m. to 5 p.m. CST from Monday to Friday)
icon of address
Address
7505 Fannin St., Ste 610, Room 7 (CUBIO Innovation Center), Houston, TX 77054, USA
icon of social media
Join us with

Subscribe newsletter

Leave a message

* To protect against spam, please pass the CAPTCHA test below.
CAPTCHA verification
© 2007-2024 CUSABIO TECHNOLOGY LLC All rights reserved. 鄂ICP备15011166号-1
Place an order now

I. Product details

*
*
*
*

II. Contact details

*
*

III. Ship To

*
*
*
*
*
*
*

IV. Bill To

*
*
*
*
*
*
*
*